O E Babalola

Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos

O E Babalola, Christopher Bode, A.A. Ajayi et al. · QJM · 2021 · 77 citations · Full text

A comparison of the Goldmann applanation and non‐contact (Keeler Pulsair EasyEye) tonometers and the effect of central corneal thickness in indigenous African eyes

O E Babalola, AV Kehinde, A. C. Iloegbunam et al. · Ophthalmic and Physiological Optics · 2009 · 53 citations

Distribution and aetiology of blindness and visual impairment in mesoendemic onchocercal communities, Kaduna State, Nigeria. Kaduna Collaboration for Research on Onchocerciasis.

A Abiose, Ian Murdoch, O E Babalola et al. · British Journal of Ophthalmology · 1994 · 49 citations · Full text

Field Trial, Ocular Disease, Blindsight +10

Ocular onchocerciasis: current management and future prospects

O E Babalola · Clinical ophthalmology · 2011 · 40 citations · Full text

Impact of annual dosing with ivermectin on progression of onchocercal visual field loss.

Simon Cousens, A Cassels-Brown, Ian Murdoch et al. · PubMed · 1997 · 33 citations

Ocular Disease, Ophthalmology, Experimental Ophthalmology +7